Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evexomostat Combination Therapy in HR+/HER2- Metastatic Breast Cancer
NCT05455619Phase 2Recruiting
- Sponsor
- SynDevRx, Inc.
- Start
- Aug 2022
- Primary completion
- Dec 2026
- Modality
- Polymer-based Nanoparticles, Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of evexomostat in breast cancer, sponsored by SynDevRx, Inc.. Started Aug 2022; status: recruiting.
02
Drugs
evexomostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05455619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05455619.